Integra LifeSciences (IART) Competitors

Integra LifeSciences logo
$13.55 -0.31 (-2.24%)
Closing price 04:00 PM Eastern
Extended Trading
$13.56 +0.00 (+0.04%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IART vs. ITGR, PLSE, TMDX, AXGN, and ATRC

Should you buy Integra LifeSciences stock or one of its competitors? Integra LifeSciences's main competitors and comparable companies include Integer (ITGR), Pulse Biosciences (PLSE), TransMedics Group (TMDX), AxoGen (AXGN), and AtriCure (ATRC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Integra LifeSciences compare to Integer?

Integra LifeSciences (NASDAQ:IART) and Integer (NYSE:ITGR) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

In the previous week, Integer had 10 more articles in the media than Integra LifeSciences. MarketBeat recorded 13 mentions for Integer and 3 mentions for Integra LifeSciences. Integer's average media sentiment score of 0.79 beat Integra LifeSciences' score of 0.00 indicating that Integer is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Integra LifeSciences
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Integer
6 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Integer has a net margin of 5.68% compared to Integra LifeSciences' net margin of 0.79%. Integra LifeSciences' return on equity of 18.63% beat Integer's return on equity.

Company Net Margins Return on Equity Return on Assets
Integra LifeSciences0.79% 18.63% 5.49%
Integer 5.68%11.84%5.98%

Integer has higher revenue and earnings than Integra LifeSciences. Integer is trading at a lower price-to-earnings ratio than Integra LifeSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integra LifeSciences$1.64B0.64-$516.47M$0.1779.71
Integer$1.85B2.33$102.81M$2.9842.61

Integra LifeSciences presently has a consensus price target of $16.13, suggesting a potential upside of 19.00%. Integer has a consensus price target of $113.67, suggesting a potential downside of 10.49%. Given Integra LifeSciences' higher possible upside, analysts clearly believe Integra LifeSciences is more favorable than Integer.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Integra LifeSciences
3 Sell rating(s)
5 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
1.90
Integer
0 Sell rating(s)
11 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.08

84.8% of Integra LifeSciences shares are held by institutional investors. Comparatively, 99.3% of Integer shares are held by institutional investors. 3.8% of Integra LifeSciences shares are held by insiders. Comparatively, 1.1% of Integer shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Integra LifeSciences has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market. Comparatively, Integer has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market.

Summary

Integer beats Integra LifeSciences on 10 of the 16 factors compared between the two stocks.

How does Integra LifeSciences compare to Pulse Biosciences?

Pulse Biosciences (NASDAQ:PLSE) and Integra LifeSciences (NASDAQ:IART) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

77.0% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 84.8% of Integra LifeSciences shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by insiders. Comparatively, 3.8% of Integra LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Pulse Biosciences has higher earnings, but lower revenue than Integra LifeSciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Integra LifeSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulse Biosciences$350K9,332.44-$72.78M-$1.21N/A
Integra LifeSciences$1.64B0.64-$516.47M$0.1779.71

Pulse Biosciences currently has a consensus price target of $66.60, indicating a potential upside of 49.97%. Integra LifeSciences has a consensus price target of $16.13, indicating a potential upside of 19.00%. Given Pulse Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Pulse Biosciences is more favorable than Integra LifeSciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pulse Biosciences
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Integra LifeSciences
3 Sell rating(s)
5 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
1.90

In the previous week, Pulse Biosciences had 1 more articles in the media than Integra LifeSciences. MarketBeat recorded 4 mentions for Pulse Biosciences and 3 mentions for Integra LifeSciences. Pulse Biosciences' average media sentiment score of 0.70 beat Integra LifeSciences' score of 0.00 indicating that Pulse Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pulse Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Integra LifeSciences
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Integra LifeSciences has a net margin of 0.79% compared to Pulse Biosciences' net margin of -5,603.88%. Integra LifeSciences' return on equity of 18.63% beat Pulse Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Pulse Biosciences-5,603.88% -77.88% -67.89%
Integra LifeSciences 0.79%18.63%5.49%

Pulse Biosciences has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market. Comparatively, Integra LifeSciences has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market.

Summary

Pulse Biosciences beats Integra LifeSciences on 10 of the 16 factors compared between the two stocks.

How does Integra LifeSciences compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and Integra LifeSciences (NASDAQ:IART) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

TransMedics Group presently has a consensus target price of $113.30, indicating a potential upside of 20.51%. Integra LifeSciences has a consensus target price of $16.13, indicating a potential upside of 19.00%. Given TransMedics Group's stronger consensus rating and higher probable upside, analysts plainly believe TransMedics Group is more favorable than Integra LifeSciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TransMedics Group
0 Sell rating(s)
7 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.42
Integra LifeSciences
3 Sell rating(s)
5 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
1.90

TransMedics Group has higher earnings, but lower revenue than Integra LifeSciences. TransMedics Group is trading at a lower price-to-earnings ratio than Integra LifeSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TransMedics Group$605.49M5.39$190.29M$3.6925.48
Integra LifeSciences$1.64B0.64-$516.47M$0.1779.71

In the previous week, TransMedics Group and TransMedics Group both had 3 articles in the media. TransMedics Group's average media sentiment score of 0.28 beat Integra LifeSciences' score of 0.00 indicating that TransMedics Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TransMedics Group
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Integra LifeSciences
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

TransMedics Group has a net margin of 19.85% compared to Integra LifeSciences' net margin of 0.79%. Integra LifeSciences' return on equity of 18.63% beat TransMedics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
TransMedics Group19.85% 13.30% 4.93%
Integra LifeSciences 0.79%18.63%5.49%

TransMedics Group has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market. Comparatively, Integra LifeSciences has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market.

99.7% of TransMedics Group shares are held by institutional investors. Comparatively, 84.8% of Integra LifeSciences shares are held by institutional investors. 6.9% of TransMedics Group shares are held by company insiders. Comparatively, 3.8% of Integra LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

TransMedics Group beats Integra LifeSciences on 11 of the 15 factors compared between the two stocks.

How does Integra LifeSciences compare to AxoGen?

AxoGen (NASDAQ:AXGN) and Integra LifeSciences (NASDAQ:IART) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

In the previous week, AxoGen had 4 more articles in the media than Integra LifeSciences. MarketBeat recorded 7 mentions for AxoGen and 3 mentions for Integra LifeSciences. AxoGen's average media sentiment score of 0.56 beat Integra LifeSciences' score of 0.00 indicating that AxoGen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AxoGen
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Integra LifeSciences
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Integra LifeSciences has a net margin of 0.79% compared to AxoGen's net margin of -11.96%. Integra LifeSciences' return on equity of 18.63% beat AxoGen's return on equity.

Company Net Margins Return on Equity Return on Assets
AxoGen-11.96% -5.35% -4.41%
Integra LifeSciences 0.79%18.63%5.49%

AxoGen has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market. Comparatively, Integra LifeSciences has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market.

AxoGen has higher earnings, but lower revenue than Integra LifeSciences. AxoGen is trading at a lower price-to-earnings ratio than Integra LifeSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AxoGen$225.21M14.93-$15.70M-$0.65N/A
Integra LifeSciences$1.64B0.64-$516.47M$0.1779.71

80.3% of AxoGen shares are owned by institutional investors. Comparatively, 84.8% of Integra LifeSciences shares are owned by institutional investors. 2.4% of AxoGen shares are owned by insiders. Comparatively, 3.8% of Integra LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

AxoGen presently has a consensus target price of $58.67, suggesting a potential upside of 4.19%. Integra LifeSciences has a consensus target price of $16.13, suggesting a potential upside of 19.00%. Given Integra LifeSciences' higher probable upside, analysts clearly believe Integra LifeSciences is more favorable than AxoGen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AxoGen
1 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.75
Integra LifeSciences
3 Sell rating(s)
5 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
1.90

Summary

Integra LifeSciences beats AxoGen on 10 of the 16 factors compared between the two stocks.

How does Integra LifeSciences compare to AtriCure?

Integra LifeSciences (NASDAQ:IART) and AtriCure (NASDAQ:ATRC) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

In the previous week, AtriCure had 3 more articles in the media than Integra LifeSciences. MarketBeat recorded 6 mentions for AtriCure and 3 mentions for Integra LifeSciences. AtriCure's average media sentiment score of 0.22 beat Integra LifeSciences' score of 0.00 indicating that AtriCure is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Integra LifeSciences
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
AtriCure
1 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

84.8% of Integra LifeSciences shares are held by institutional investors. Comparatively, 99.1% of AtriCure shares are held by institutional investors. 3.8% of Integra LifeSciences shares are held by company insiders. Comparatively, 4.0% of AtriCure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

AtriCure has lower revenue, but higher earnings than Integra LifeSciences. Integra LifeSciences is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integra LifeSciences$1.64B0.64-$516.47M$0.1779.71
AtriCure$534.53M5.15-$11.45M$0.30180.37

AtriCure has a net margin of 2.52% compared to Integra LifeSciences' net margin of 0.79%. Integra LifeSciences' return on equity of 18.63% beat AtriCure's return on equity.

Company Net Margins Return on Equity Return on Assets
Integra LifeSciences0.79% 18.63% 5.49%
AtriCure 2.52%4.01%3.03%

Integra LifeSciences has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market. Comparatively, AtriCure has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market.

Integra LifeSciences presently has a consensus price target of $16.13, suggesting a potential upside of 19.00%. AtriCure has a consensus price target of $62.30, suggesting a potential upside of 15.14%. Given Integra LifeSciences' higher probable upside, analysts clearly believe Integra LifeSciences is more favorable than AtriCure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Integra LifeSciences
3 Sell rating(s)
5 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
1.90
AtriCure
1 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.58

Summary

AtriCure beats Integra LifeSciences on 12 of the 17 factors compared between the two stocks.

Get Integra LifeSciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for IART and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IART and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IART vs. The Competition

MetricIntegra LifeSciencesHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.08B$5.92B$7.59B$11.70B
Dividend YieldN/A1.69%2.48%4.65%
P/E Ratio79.7135.5231.9526.73
Price / Sales0.645.328.405.55
Price / Cash3.2823.4220.7221.66
Price / Book0.994.154.423.65
Net Income-$516.47M$143.14M$3.51B$394.00M
7 Day Performance-5.57%-5.25%-6.16%-6.39%
1 Month Performance0.74%-5.76%-7.05%-8.77%
1 Year Performance21.52%-1.61%-2.52%-8.48%

Integra LifeSciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IART
Integra LifeSciences
1.9333 of 5 stars
$13.55
-2.2%
$16.13
+19.0%
+21.4%$1.08B$1.64B79.714,427
ITGR
Integer
1.0982 of 5 stars
$126.70
+0.1%
$113.67
-10.3%
+87.1%$4.31B$1.85B42.5011,000
PLSE
Pulse Biosciences
3.561 of 5 stars
$54.09
-7.0%
$66.60
+23.1%
+237.5%$3.83B$350KN/A116
TMDX
TransMedics Group
3.2014 of 5 stars
$91.22
-2.7%
$113.30
+24.2%
-17.6%$3.15B$605.49M24.72898
AXGN
AxoGen
2.01 of 5 stars
$50.41
-0.4%
$57.92
+14.9%
+137.2%$3.01B$225.21MN/A622

Related Companies and Tools


This page (NASDAQ:IART) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners